Clarinex RediTabs launched for indoor and outdoor allergies and chronic idiopathic urticaria
KENILWORTH, N.J., May 29 2003 -- Schering-Plough announced that it has begun shipping Clarinex 5 mg RediTabs tablets, a convenient, orally disintegrating tablet formulation of the prescription nonsedating antihistamine desloratadine, to wholesalers and other trade accounts across the United States.
Clarinex 5 mg RediTabs is the first orally disintegrating prescription antihistamine approved for the treatment of allergy symptoms caused by both perennial indoor and seasonal outdoor allergens and chronic idiopathic urticaria (CIU), or hives of unknown cause, in adults and children 12 years of age and older. Clarinex RediTabs will be available in pharmacies nationwide by the first week of June.
Clarinex 5 mg RediTabs complements Clarinex 5 mg Tablets as the second formulation of the Clarinex family. Because Clarinex RediTabs can be taken without water, the product is particularly convenient for allergy sufferers who may have trouble swallowing pills or who lead active lifestyles where access to water is not always readily available.
Clarinex is the only prescription nonsedating antihistamine approved for the treatment of indoor and outdoor allergies and CIU. The efficacy and safety of Clarinex in outdoor allergies has been established in four double-blind, randomized, placebo-controlled studies involving more than 2,300 patients with seasonal allergies. Clarinex was also studied in indoor allergies in two double-blind, randomized, placebo-controlled studies involving more than 1,300 patients with perennial allergies. A single 5 mg dose of Clarinex taken once daily provides 24-hour nonsedating relief from nasal and non-nasal symptoms of indoor and outdoor allergies. The approval for Clarinex in CIU was based on two double-blind, randomized, placebo-controlled studies involving more than 400 patients.
Full Prescribing Information is available at: www.spfiles.com/piClarinex.pdf
Source: Schering-Plough Corporation
Posted: May 2003